S Ketamine Use in Total Abdominal Hysterectomy

• Status: Withdrawn
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study investigates the effect of low dose S+ketamine compared to placebo on cumulative morphine consumption at 24 hours in women undergoing open abdominal hysterectomy with remifentanil-propofol target controlled infusion. It compares the adverse effect profile in patients receiving S+ketamine as compared to those who did not. Participants are randomly distributed in two groups of 45 patient's each.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: KK Women's and Children's Hospital
• Treatments: Esketamine; Ketamine; Morphine

Criteria

Inclusion Criteria:

• Females above the age of 21 years old scheduled undergoing open abdominal hysterectomy with remifentanil-propofol TCI in KKH for benign condition (fibroids, adenomyosis),

• Be willing and able to give written informed consent for participation in this study

• ASA I/II patient's.

Exclusion Criteria:

• Patient with contraindications to the use of S+ketamine, as listed in the product label e.g. untreated or insufficiently treated thyroid hyperfunction, unstable angina pectoris or myocardial infarction within the last 6 months, diseases of the CNS, increased intraocular pressure and perforating ocular injuries, surgical procedures in the upper respiratory tract, etc

• Patients with a h/o drug or alcohol abuse

• Regular use of analgesics, or use of opioids within 12 hours of surgery

• Patient on chronic use of benzodiazepine or neurololeptics

• Patient on thyroid replacement hormone

• H/o IHD,HTN,Thyroid disorder.

• BMI> 30kg/m2.

• H/o Psychiatric disorder.

• Laproscopic surgery converted to open surgery.

• Pregnant or breast feeding female's.